Allogeneic or autologous stem cell transplantation (SCT) for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma: a single-centre experience Nachbaur D, Oberaigner W, Fritsch E, Nussbaumer W, Gastl G. Allogeneic or autologous stem cell transplantation (SCT) for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma: a single-centre experience. Abstract: Purpose of the study: The aim of the study was to evaluate which patient might bene®t most from allogeneic stem cell transplantation (SCT) in the treatment of relapsed and/or refractory lymphoma. Patients and methods: Thirty-eight consecutive lymphoma patients receiving either autologous (n=24) or allogeneic (n=14) stem cell grafts at our institution from 1986 to 1998 were retrospectively analysed regarding overall survival (OS), disease-free survival (DFS), transplantrelated mortality (TRM), and relapse incidence (RI). Uni-and multivariate analyses were performed to identify patient characteristics predictive for outcome after SCT. Results: The probabilities of OS, DFS, TRM, and relapse were 57%, 51%, 29%, and 30% following autologous and 43%, 43%, 29%, and 38% following allogeneic SCT. Disease status (sensitive versus refractory) and the time interval between diagnosis and SCT were the most powerful predictive parameters for OS and TRM, whereas elevated serum LDH levels were signifcant in determining relapse. Conclusions: In patients with elevated serum LDH levels and bone marrow involvement at the time of transplantation allogeneic was superior to autologous SCT and resulted in better outcome due to a lower relapse incidence strongly suggesting the existence of a graftversus-lymphoma effect. High-dose chemo/radiotherapy with autologous stem cell rescue offers a reliable chance of longterm disease-free survival for patients with relapsing or refractory Hodgkin's disease (HD) or nonHodgkin's lymphoma (NHL) who otherwise have a poor prognosis (1±4). During the past decade several studies have demonstrated the relative effectiveness of this approach and its advantages over conventional-dose salvage regimens in selected patients (5±9). In contrast, allogeneic SCT is used only sporadically because of its higher TRM and the risk of developing acute and/or chronic graftversus-host disease (GVHD) (10±17). Potential graft-versus-lymphoma (GVL) effects associated with allogeneic SCT are supposed in some series but warrant con®rmation by prospective, randomized trials (18±21). To de®ne better the role of allogeneic SCT in the management of poor-risk lymphoma we here report on our experience obtained in 38 consecutive patients transplanted at our institution from 1986 to 1998.
High-dose chemo/radiotherapy with autologous stem cell rescue offers a reliable chance of longterm disease-free survival for patients with relapsing or refractory Hodgkin's disease (HD) or nonHodgkin's lymphoma (NHL) who otherwise have a poor prognosis (1±4). During the past decade several studies have demonstrated the relative effectiveness of this approach and its advantages over conventional-dose salvage regimens in selected patients (5±9). In contrast, allogeneic SCT is used only sporadically because of its higher TRM and the risk of developing acute and/or chronic graftversus-host disease (GVHD) (10±17). Potential graft-versus-lymphoma (GVL) effects associated with allogeneic SCT are supposed in some series but warrant con®rmation by prospective, randomized trials (18±21). To de®ne better the role of allogeneic SCT in the management of poor-risk lymphoma we here report on our experience obtained in 38 consecutive patients transplanted at our institution from 1986 to 1998. allogeneic, HLA-identical (n=14) stem cell grafts. Preference was generally given to an allograft when patients were candidates for both types of graft. All patients were classi®ed as having poor prognosis de®ned as either primary refractory or achieving only partial recovery (PR) after initial standard treatment, or as disease relapsing within one year from diagnosis after achieving complete remission (CR) following initial chemotherapy, or as patients with second or subsequent relapse. Patients with NHL were classi®ed according to the updated Kiel classi®cation and patients with HD according to the Rye classi®cation (22, 23) . Patient characteristics are detailed in Tables 1 and 2 .
Preparative regimens and stem cell infusion
For patients with previous dose-limiting radiation therapy the standard preparative regimen was highdose cyclophosphamide, carmustine, and etoposide (CBV, consisting of 100 mg/kg CY, 15 mg/kg BCNU, and 60 mg/kg etoposide) followed by either autologous (n=15) or allogeneic (n=2) SC infusion (24) . Patients without prior dose-limiting radiotherapy received a combination of high-dose CY (100 mg/kg), etoposide (60 mg/kg), and fractionated TBI (fTBI, 12 Gy, given in six fractions over three consecutive days) followed by either allogeneic (n=6) or autologous (n=9) SCT. Standard highdose CY(120 mg/kg) plus fTBI (12 Gy) was given prior to ®ve allogeneic and one autologous SCT.
One patient received a combination of BU (8 mg/ kg), CY (100 mg/kg), and single-dose TBI (10 Gy) followed by allogeneic stem cell infusion.
Allografted , n=12) or DHAP (n=3) plus G-CSF according to recently published standard procedures (25) .
Relapse prophylaxis
Patients with radiological (CT scan) evidence of localised disease at the time of SCT underwent involved-®eld irradiation (20±30 Gy) starting as soon as possible within the ®rst three months after hematopoietic regeneration.
Supportive care including graft-versus-host disease prophylaxis
Patients receiving autologous SCT were treated under strict reverse isolation without laminar airow. Patients receiving allografts were nursed in laminar air¯ow rooms from the beginning of the conditioning regimen until hematopoietic regeneration. No prophylactic systemic antibiotics were administered. All patients underwent a non-absorbable oral gut decontamination with vancomycin, gentamycin, and nystatin. Pneumocystis carinii prophylaxis was performed with trimethoprimsulfamethoxazole given in a 10-d course before transplantation and after the take. Cytomegalovirus (CMV) pneumonia prophylaxis consisted of infusions of CMV hyperimmunoglobulin (Cytotect, Cutter, 1 ml/kg) every other week until day +100. Irradiated (25 Gy), leukocyte-depleted and CMVnegative red cells and platelet transfusions from single donors were administered when hemoglobin levels were 7.0 g/dL or less and platelets were 20 G/L or less. To accelerate hematopoietic regeneration G-CSF (5 mg/kg/d) was given to 3/14 (21%) allografted and to 22/24 (92%) autografted patients starting on the day after SC infusion. GVHD prophylaxis consisted of cyclosporine A (CsA) alone (n=11) or in combination with shortcourse methotrexate (MTX) according to the Seattle protocol (n=3). Grading and treatment of acute and chronic GVHD was performed according to the standard Seattle criteria and protocols.
Statistics
Survival analyses were performed according to the method of Kaplan and Meier (26) . Overall survival (OS) was calculated from the date of SCT to the date of death from any cause or day of last follow-up. Disease/progression free survival (DFS) was calculated from the date of SCT to the date of documented disease relapse/progression. Transplant-related mortality was de®ned as the probability of death without relapse or disease progression. For two patients receiving a second graft (one autologous and one allogeneic) because of disease progression/relapse after autologous SCT the unit studied was the patient and the censored data correspond to the date of the last contact for each patient according to the recently published European Group for Blood and Marrow Transplantation (EBMT) statistical guidelines (27) .
Univariate analysis of the following parameters was performed using the log-rank test and SPSS software to identify patient characteristics predictive for outcome after SCT: diagnosis (HD vs. NHL), stem cell source (allogeneic vs. autologous), disease status at the time of SCT (SD vs. RD/PD), conditioning regimen (TBI-containing vs. chemotherapy alone), number of previous lines of treatement (1±2 vs. o3), BM involvement at the time of SCT (yes vs. no), and serum LDH levels at the time of SCT (f240 IU/L vs. >240 IU/L). For the variable``age'' the median age (40 yr) of the whole study population was chosen as cut-off. For the variable``time interval between diagnosis and SCT'' an interval of 3 yr was chosen because the greatest difference in overall survival was observed between patients receiving a transplant within or beyond this time frame.
Multivariate analysis was performed using Cox's proportional hazards model. The factors examined were the same as those included in the univariate analysis.
Results
Hematological engraftment, overall survival (OS), and diseasefree survival (DFS)
All but four patients dying too early because of regimen-related toxicity and/or infection engrafted (de®ned as the ®rst day with a persistent leukocyte count >1.0 G/L) after a median of 16 d (range 12± 29) following allogeneic and a median of 15 d (range 9±37) following autologous SCT. The probability of OSt95% con®dence interval (CI) for all patients was 51t8% with an actuarial survival at 3 yr of 57t11% vs. 43t13% following autologous vs. allogeneic SCT (Fig. 1) and a disease/progression-free survival of 51t10% vs. 43t13%.
The most powerful predictive parameters for survival following SCT were disease status and time interval from diagnosis to SCT (pf0.05, log-rank test, Fig. 2 and Table 3 ). Younger age, non-TBIcontaining conditioning, normal serum LDH levels, and absence of bone marrow involvement were also associated with improved survival but did not reach statistical signi®cance (Table 3) .
Allogeneic SCT was superior to autologous SCT only in patients with elevated serum LDH levels >240 IU/L (overall survival 33t27% vs. 20t18%, difference not signi®cant) and BM involvement at the time of SCT (overall survival 75t22% vs. 0%, p=0.091) mainly due to a lower RI.
For HD patients, OS following allogeneic vs. autologous SCT was 40t22% vs. 67t15%. For patients with NHL, survival following allogeneic and autologous SCT was 44t17% and 47t15%, respectively. Overall survival following autologous SCT was 42t21% for patients with low-grade lymphoma vs. 57t16% for high-grade lymphoma.
Survival for patients with sensitive disease receiving allografts and autografts was 67t21% and 78t18%, respectively, whereas survival in patients with refractory disease was only 25t13% following allo-and 22t12% following autotransplantation (differences not signi®cant). Also for all other variables listed in Table 3 survival was not different between auto-and allotransplantation.
Relapse incidence (RI) and graft-versus-host disease (GVHD)
The probability of relapse/progression (t95% CI) at 3 yr for the entire study cohort was 34t9%, with a RI of 38t15% vs. 31t11% following allogeneic vs. autologous SCT (Fig. 1) .
The only factor signi®cantly determining RI was serum LDH level with a signi®cantly higher RI in patients with elevated serum LDH levels (71t23% vs. 25t9%, p=0.048, Table 3 ). Also patients with refractory disease had a higher RI (51t17% vs. 25t10%), but this did not reach statistical signi®cance (Fig. 2, Table 3 ). There was a trend for a lower RI following allotransplantation in patients with elevated serum LDH levels (33t15% vs. 73t22% for autologous transplantation, difference not signi®cant) and in patients with BM involvement (0% vs. 47t15% for autologous transplantation, difference not signi®-cant). We also observed a trend for a lower RI in HD patients following allotransplantation (33t27% vs. 43t19% following autologous SCT), whereas for NHL patients the incidence of relapse following allogeneic SCT was even higher than following autologous SCT (43t19% vs. 24t12%), but there were more high-grade lymphomas in the allogroup (78% vs. 47%). For none of the variables listed in Table 3 was relapse incidence signi®cantly different between allo-and autotransplantation.
Acute GVHD (aGVHD) grades I±II developed in 7/14 allografted patients after a median of 22 (1± 27) d. None of the patients developed aGVHD grades III±IV or died due to GVHD, and only one patient had laboratory signs of limited chronic GVHD of the liver requiring prolonged administration of CsA. Interestingly, 4/7 allografted patients without aGVHD died of relapse/progression, whereas none of the allografted patients with evidence of aGVHD relapsed within the study period.
Transplant-related mortality (TRM) and causes of death
Eighteen patients died within the observation period. The causes of death in the allogroup were relapse/progression (n=4), viral interstitial pneumonitis (n=3), and septical multiorgan failure (n=1), whereas in the autogroup three patients died of relapse/progression, six patients due to infectious complications and one patient died of cardiac toxicity.
Sensitivity of disease and disease duration were the only variables associated with a signi®cantly lower TRM following SCT (Table 3) .
As shown in Fig. 1 , TRM was similar following allogeneic and autologous SCT. There was a trend for a higher TRM in patients with HD receiving allografts (40t22% vs. 22t14% following autologous SCT, difference not signi®cant).
For all other variables listed in Table 3 no signi®cant differences in TRM between allogeneic and autologous SCT were observed.
Discussion
In accordance with other reports, sensitive disease was the most powerful predictive parameter for survival after SCT for poor-risk lymphoma (2±5, 14, 15, 21) . Additionally, our data demonstrate that a shorter disease duration was associated with favourable outcome, indicating that high-dose chemotherapy with stem-cell support should be offered early to patients with relapsing and/or refractory lymphoma. As suspected, for both variables the better outcome resulted from a signi®cantly lower transplant-related mortality not only following autologous but also allogeneic SCT.
To date there is no answer to the question of which lymphoma patient should receive and would bene®t most from allogeneic SCT if both treatment modalities are available. Although there is some evidence supporting the concept of a graft-versuslymphoma (GVL) effect at least in selected subgroups, so far no prospective study has proved any survival advantage of allogeneic over autologous SCT because of a higher procedure-related mortality (10, 18±21).
Although in our study differences between autoand allotransplantation with regard to any of the variables tested by uni-and multivariate analysis were statistically not signi®cant because of the small patient numbers in the individual subgroups, the improved survival due to a lower relapse incidence following allotransplants in patients with elevated serum LDH levels and bone marrow involvement at the time of SCT supports the hypothesis of a GVL effect. Whether such an effect also exists in Hodgkin's disease as supposed from the lower RI found in HD patients receiving allografts remains to be shown. Irrespectively, the fact that none of the allografted patients developing clinical GVHD relapsed compared with 4/7 patients without GVHD strongly argues in favour of the existence of either tumor-speci®c (tumor antigen-directed) or unspeci®c (minor antigen-directed) antitumor effects mediated by the graft. Interestingly, in contrast to other published series we did not ®nd a higher treatment-related mortality following allografting with the exception of HD patients, but this difference did not reach statistical signi®cance (18, 20, 21) . Nonetheless, treatmentrelated mortality remains high and accounted for 50% of all deaths in the allogroup and for 70% of all deaths in the autogroup, and was de®nitively only acceptable in patients with sensitive disease. Whether graft manipulation by either T-cell depletion or CD34
+ selection with or without graded T-cell add-back can overcome these shortcomings at least in the allogeneic setting of SCT without any negative effect on relapse/progression or infectious complications remains to be seen (28) .
Disease relapse/progression is the second major factor contributing to treatment failure following both types of SCT. All but one relapsing patient receiving a second autologous transplant died within weeks to months due to progressive disease, requiring alternative treatment strategies for those patients. Donor lymphocyte infusions (DLI) alone or in combination with chemotherapy might work after allogeneic SCT as shown by some recent reports but are far from being successful in all relapsing patients (29, 30) . Recurrence after autologous SCT might be effectively salvaged by allogeneic or a second autologous SCT with acceptable toxicity, but long-term outcome remains poor (31, 32) .
In conclusion, our results support the existence of a graft-versus-lymphoma effect and identify patients with elevated serum LDH levels and bone marrow involvement as those patients who might bene®t most from allogeneic SCT when using standard procedures. The results, however, are preleminary and must be interpreted with caution due to the small patient number unless they have been con®rmed by larger prospective, randomized studies. Recent advances especially the introduction of alternative, less toxic treatment modalities such as non-myeloablative conditioning will help to reduce toxicity and to clarify the mechanisms involved in graft-versus lymphoma effects and will inevitably increase the number of allogeneic transplants in the treatment of malignant lymphoma (33, 34) .
